European Science Foundation is seeking applications for Fight Kick Cancer programme which is
an exciting venture supported by three European NGO’s that have joined forces
to launch an opportunity to support academic research for paediatric cancers.
Their vision is to cure all children and adolescents with cancer
through the development of better targeted and less toxic therapies. Fight
Kids Cancer’s mission will be to catalyze and accelerate European research that
results in innovative and impactful new therapies that improve the outcome for
all children and adolescents with cancer.
Objectives
The Fight Kids Cancer programme (hereafter
“FKC”) aims to catalyze and support pan-European innovative and
relevant research initiatives in pediatric cancer to develop innovative
research that improves the outcome for all children and adolescents with
cancer. This call will cover the following non-exclusive themes:
- To realize real impact on young
patients: Improve survival rate & reduce toxicity to restore young
patients to full health after treatment
- To produce cutting-edge science
to advance knowledge of pediatric malignancies.
- To support improved
interdisciplinary knowledge, methods and collaborations for tackling the
issues of today.
- To strengthen collaboration and
the development of scientific capacity across Europe.
Priorities
This call aims to prioritize areas that will
effectively benefit young patients by:
- improving their survival
rate
- improving their quality of life
during and after the treatments
- improving our knowledge on
cancer causes and treatment resistance
Project Categories
Projects are expected to propose research on
either early phase clinical trials or Translational research. Applicants to
both categories are encouraged to address innovative interventions or
approaches towards novel treatment (such as innovative drugs, artificial
intelligence, imaging, radiotherapy, surgical approaches…). The two categories
of projects are:
- Early phase clinical trials into evaluating innovative therapies for children and
adolescents with cancer addressing hematological malignancies, solid
pediatric and adolescent cancers.
- Documentation for provision of
investigational drug(s) must be provided
- Demonstration that the trial
is conducted and financed in at least 2 European countries
- Co-funding of clinical trials
is possible, however precise details, justification and timeline must be
provided
- Enrolment of patients must
commence not later than 12 months from the start of funding
- Translational research projects
addressing either hematological malignancy, solid pediatric and adolescent
cancers. Proposals are encouraged on:
- Projects identifying novel
mechanisms of action
- Projects that may result in
innovative new therapies or better models of disease.
- Pre-clinical projects
including high-risk / high return proposals,
- Projects that leverage
pediatric tumor models will be considered.
- Multi-disciplinary or
multi-institution collaborations are strongly encouraged.
Funding Information
For this call, 3 million
euros will be awarded for clinical trials (with a maximum of 1,5 million per
project) and translational projects (with a maximum of 500 000 euros per
project).
Eligibility Criteria
- Funding is aimed at supporting
new research projects across Europe. The lead institution must be from the
list of eligible countries, with preference given to institutions with a
strong track record in pediatric cancer research. Other project partners
are encouraged and can be from related fields of expertise, providing they
operate as not-for-profit. See Guidance for Applicants for details.
- Eligible countries included
are: Austria, Belgium, Bulgaria, Croatia, Cyprus, Czechia, Denmark, Estonia,
Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Israel,
Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Norway, Poland,
Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, Switzerland, and
United Kingdom.
Post Date - 08-Oct-2020